Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc. News
Jun 11, 2025 - https://www.defenseworld.net
19,564 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Purchased by Squarepoint Ops LLC
Apr 28, 2025 - globenewswire.com
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million
Aerovate Therapeutics, Inc. Quantitative Score
About Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Aerovate Therapeutics, Inc. Financials
Table Compare
Compare AVTE metrics with: | |||
|---|---|---|---|
Earnings & Growth | AVTE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | AVTE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | AVTE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | AVTE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Aerovate Therapeutics, Inc. Income
Aerovate Therapeutics, Inc. Balance Sheet
Aerovate Therapeutics, Inc. Cash Flow
Aerovate Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Aerovate Therapeutics, Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 84.0000 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| TBA | 84 | Quarterly |
Historical Market Cap
Shares Outstanding
Aerovate Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Mr. Timothy P. Noyes M.B.A. | Chief Executive Officer & Director |
| Mr. George A. Eldridge | Chief Financial Officer & Treasurer |
| Mr. Hunter Gillies M.D. | Chief Medical Officer |
| Dr. Benjamin T. Dake Ph.D. | Founder, President, Chief Operating Officer & Secretary |
| Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Scientific Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Timothy P. Noyes M.B.A. | Chief Executive Officer & Director | Male | 1962 | 936.9K |
| Mr. George A. Eldridge | Chief Financial Officer & Treasurer | Male | 1963 | 658.6K |
| Mr. Hunter Gillies M.D. | Chief Medical Officer | Male | 1966 | 512.74K |
| Dr. Benjamin T. Dake Ph.D. | Founder, President, Chief Operating Officer & Secretary | 1976 | 435.5K | |
| Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Scientific Officer | 1960 | 372.33K |
Aerovate Therapeutics, Inc. Insider Trades
| Date | 31 Jul |
| Name | Dake Benjamin T |
| Role | SEE REMARKS |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 11454 |
| Date | 1 Aug |
| Name | Dake Benjamin T |
| Role | SEE REMARKS |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 1507 |
| Date | 1 Aug |
| Name | Dake Benjamin T |
| Role | SEE REMARKS |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 1507 |
| Date | 31 Jul |
| Name | Dake Benjamin T |
| Role | SEE REMARKS |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 10548 |
| Date | 17 Jun |
| Name | RA CAPITAL MANAGEMENT, L.P. |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 928110 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 31 Jul | Dake Benjamin T | SEE REMARKS | Acquired | M-Exempt | 11454 |
| 1 Aug | Dake Benjamin T | SEE REMARKS | Acquired | M-Exempt | 1507 |
| 1 Aug | Dake Benjamin T | SEE REMARKS | Disposed | M-Exempt | 1507 |
| 31 Jul | Dake Benjamin T | SEE REMARKS | Disposed | M-Exempt | 10548 |
| 17 Jun | RA CAPITAL MANAGEMENT, L.P. | Director, 10 percent owner | Acquired | P-Purchase | 928110 |